Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele (CARPEDIEM)

N/AActive Not RecruitingNCT06481345

University Hospital, Brest300 enrolled

Overview

Retrospective study assessing the impact of IDH1/2, SRSF2 or SF3B1 mutations on event free survival of MPN patients

Patients with a diagnosis of MPN and a mutation of IDH1/2, SRSF2 or SF3B1 will be included. Clinical and biological characterisation at diagnosis, as well as evlution will be recorded. Event free survival will be assessed in each group (event = thrombosis, transformation to mylofibrosis/acute leukemia, death).

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Myeloproliferative Disorders

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with MPN diagnosis * Mutation in IDH1/2, SRSF2 or SF3B1 Exclusion Criteria: * Unable to consent

Locations (1)

Chu Brest

Brest, France

Outcomes

Primary Outcomes

Event free survival

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.